Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHSA/GCSF for chemotherapy-induced neutropenia in breast cancer
NCT03246009Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jan 2016
- Primary completion
- Apr 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of rHSA-GCSF in neutropenia (6 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Number of adverse events at 14 days. Started Jan 2016; status: completed.
02
Drugs
rHSA-GCSF
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03246009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246009.